A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1

Virology

Volumn 310, Issue 2, 2003, Pages 207-215

  Geffin, Rebeca ^a   Hutto, Cecelia ^a,b   Andrew, Carole ^a   Scott, Gwendolyn B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Antibodies; HIV; Immune response; Neutralization; Neutralization escape; Perinatal infection

Indexed keywords

NEUTRALIZING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIBODY TITER; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VIVO STUDY; INFANT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MATERNAL CARE; MEDICAL ASSESSMENT; NEWBORN; PERINATAL INFECTION; PLASMA; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS SURVIVAL; ANTIBODY SPECIFICITY; BLOOD; COMPARATIVE STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; PATHOLOGY; PRESCHOOL CHILD; SERODIAGNOSIS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODY SPECIFICITY; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HIV ANTIBODIES; HIV SEROPOSITIVITY; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; LONGITUDINAL STUDIES; MALE; NEUTRALIZATION TESTS;

EID: 0038002094     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0042-6822(03)00137-5     Document Type: Article

References (29)

1. Arendrup, M., Nielsen, C., Hansen, J.E., Pedersen, C., Mathiesen, L., Nielsen, J.O., 1992. Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J. Acquit. Immune Defic. Syndr. 5, 303-307.
2. Baba, T.W., Liska, V., Hofmann-Lehmann, R., Vlasak, J., Xu, W., Ayehunie, S., Cavacini, L.A., Posmer, M.R, Katinger, H., Stiegler, G., Bernacky, B.J., Rizvi, T.A., Schmidt, R., Hill, L.R., Keeling, M.E., Lu, Y., Wright, J.E., Chou, T.-C., Ruprecht, R.M., 2000. Human neutralizing monoclonal antibodies of the IgG 1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6, 200-206.
3. Beaumont, T., van Nuenen, A., Broersen, S., Blattner, W.A., Lukashov, V.V., Schuitemaker, H., 2001. Reversal of human immunodeficiency virus type 1 II1B to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course. J. Virol. 75, 2246-2252.
4. Borrow, P., Lewicki, H., Hahn, B.H, Shaw, G.M., Oldstone, M.B., 1994. Virus-specific CD 8 and cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68, 6103-6110.
5. Bradney, A.P., Scheer, S., Crawford, J.M., Buchbinder, S.P., Montefiori, D.C., 1999. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. J. Infect. Dis. 179, 1264-1267.
6. Cao, Y., Qin, L., Zhang, L.Q., Safrit, J.T., Ho, D.D., 1995. Virological and immunological characterization of long-term survivors of HIV-1 infection. N. Engl. J. Med. 332, 201-208.
7. Dreyer, K.Y., Kallas, E.G., Planelles, V., Montefiori, D., McDermott, M.P., Hasan, M.S., Evans, T.G., 1999. Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy. AIDS Res. Human Retroviruses 15, 1563-1571.
8. Fasekas de St. Groth, S., Webster, R.G., 1966. Disquisitions of original antigenic sin. 1. Evidence in man. J. Exp. Med. 124, 331-345.
9. Greenough, T.C., Brettler, D.B., Somasundaran, M., Panicali, D.L., Sullivan, J.L., 1997. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4-T cell loss: evidence supporting a protective role for CTL in vivo. J. Infect. Dis. 176, 118-125.
10. Hutto, C., Parks, W.P., Lai, S.H., Mastrucci, M.T., Mitchell, C., Munoz, J., Trapido, E., Master, I.M., Scott, G.B., 1991. A hospital-based prospective study of perinatal infection with human immunodeficiency virus type 1. J. Pediatr. 118, 347-353.
11. Klein, M.R., van Baalen, C.A., Holwerda, A.M., Kerkhof Garde, S.R., Bende, R.J., Keet, I.P., Eeftinck-Schattenberk, J.K., Osterhaus, A.D., Schuitemaker, H., Miedema, F., 1995. Kinetics of gag-specific cytotoxic lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181, 1365-1372.
12. Koup, R.A., Safrit, J.T., Cao, Y., 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650-4655.
13. Lathey, J.L., Pratt, R.D., Spector, S.A., 1997. Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with immunodeficiency virus type 1. J. Infect. Dis. 175, 231-232.
14. Locher, C.P., Grant, R.M., Collison, E.A., Reyes-Teran, G., Elbeik, T., Khan, J.O., Levy, J.A., 1999. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination. AIDS Res. Human Retroviruses 15, 1685-1689.
15. Mascola, J.R., Stiegler, G., VanCott, T.C., Katinger, H., Carpenter, C.B., Hanson, C.E., Beary, H., Hayes, D., Frankel, S.S., Birx, D.L., Lewis, M.G., 2000. Protection of macaques against vaginal transmission of a pathogenic HIV4/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6, 207-210.
16. McCarthy, M., He, J., Auger, D., Geffin, R., Woodson, C., Hutto, C., Wood, C., Scott, G., 2002. Cellular tropisms and coreceptor usage of HIV-1 isolates from vertically infected children with neurological abnormalities and rapid disease progression. J. Med. Virol. 67, 1-8.
17. Montefiofi, D.C., Hill, T.S., Vo, H.T.T., Walker, B.D., Rosenberg, E.S., 2001. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency type 1 infection. J. Virol. 75, 10200-10207.
18. Montelaro, R.C., Parekh, B., Orrego, A., Issel, C.J, 1984. Antigenic variation during persistent infection by equine infectious anemia virus, a retrovirus. J. Biol. Chem. 259, 10539-10544.
19. Moog, C., Fleury, H.J., Pellegrin, I., Kim, A., Aubertin, A.M., 1997. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type-linfected individuals. J. Virol. 71, 3734-3741.
20. Moss, P.A., Rowland-Jones, S.L., Frodsham, P.M., McAdams, S., Giangrande, P., McMichael, A.J., Bell, J.I., 1995. Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors. Proc. Natl. Acad. Sci. USA 92, 5773-5777.
21. Narayan, O., Clements, J.E., Griffin, D.E., Wolinsky, J.S., 1981. Neutralizing antibody spectrum determines the antigenic profiles of emerging mutants of visna virus. Infect. Immun. 32, 1045-1050.
22. Pantaleo, G., Menzo, S., Vaccarezza, M., Graziosi, C., Cohen, O.J., Demarest, J.F., Montefiore, D., Orenstein, J.M., Fox, C., Schrager, L.K., 1995. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N. Engl. J. Med. 332, 209-216.
23. Pellegrin, I., Legrand, E., Neau, D., Bonot, P., Masquelier, B., Pellegrin, J.L., Ragnaud, J.M., Bernard, N., Fleury, H.J., 1996. Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 11, 438-447.
24. Pilgrim, A.K., Pantaleo, G., Cohen, O.J., Fink, L.M., Zhou, J.Y., Zhou, J.T., Bolognesi, D.P., Fauci, A.S., Montefiori, D.C., 1997. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J. Infect. Dis. 176, 924-932.
25. Poignard, P., Sabble, R., Pichio, G.R., Wang, M., Gulizia, R.I., Katinger, H., Parren, P.W., Mosier, D.E., Burton, D.R., 1999. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 10, 431-438.
26. Rinaldo, C., Huang, X.L., Fan, Z.F., Ding, M., Beltz, L., Logar, A., Panicali, D., Mazzara, G., Liebmann, J., Cottrill, M., 1995. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load am associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 69, 5838-5842.
27. Salinovich, O., Payne, S.L., Montelaro, R.C., Hussain, K.A., Issel, C.J., Schnorr, K.L., 1986. Rapid emergence of novel antigenic and genetic variants of equine infectious anemia virus during persistent infection. J. Virol. 57, 71-80.
28. Shibata, R., lgarashi, T., Haigwood, N., Buckler-White, A., Ogert, R., Ross, W., Willey, R., Cho, M.W., Martin, M.A., 1999. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5, 204-210.
29. Tremblay, M., Wainberg, M.A., 1990. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. J. Infect. Dis. 162, 735-737.